Neogenomics Inc revenue
Neogenomics Inc's revenue was $727m in fiscal 2025, up 10.1% on the year before. Since fiscal 2016 ($232m) it has grown at a compound 13.5% a year. Over the last twelve months it was $788m.
Revenue history
| Fiscal year | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMSept 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 232 | 240 | 277 | 409 | 444 | 484 | 510 | 592 | 661 | 727 | 788 |
| Growth on the year before | — | +3.6% | +15.2% | +47.7% | +8.7% | +9.0% | +5.2% | +16.1% | +11.6% | +10.1% | — |
| Gross profit | 98 | 102 | 127 | 197 | 186 | 187 | 188 | 245 | 290 | 314 | 353 |
Where the revenue comes from
| Line of business | Revenue | Share | YoY |
|---|---|---|---|
| Client Direct Billing | $519M | 71.3% | ▲ 9.1% |
| Commercial Insurance | $118M | 16.2% | ▲ 17.7% |
| Medicare and Other Governmental | $90.9M | 12.5% | ▲ 7.4% |
| Self Pay Services | $114,000 | 0.0% | ▼ 83.3% |
From Neogenomics Inc's 10-K filed February 17, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Neogenomics Inc | $788m | 11.1% | 11.1% |
| Repligen Corp | $806m | 13.8% | 7.3% |
| 10x Genomics, Inc. | $617m | -4.3% | 2.8% |
| Azenta, Inc. | $614m | 4.9% | -0.9% |
| Veracyte, Inc. | $562m | 17.3% | 19.6% |
| Bio-Techne | $1.22bn | -0.4% | 2.2% |
Compare with peers
- Repligen Corp revenue
- 10x Genomics, Inc. revenue
- Azenta, Inc. revenue
- Veracyte, Inc. revenue
- Bio-Techne revenue
Head to head: NEO vs RGENNEO vs TXGAZTA vs NEONEO vs TECH
More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies